ATE476496T1 - Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten - Google Patents

Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten

Info

Publication number
ATE476496T1
ATE476496T1 AT97914841T AT97914841T ATE476496T1 AT E476496 T1 ATE476496 T1 AT E476496T1 AT 97914841 T AT97914841 T AT 97914841T AT 97914841 T AT97914841 T AT 97914841T AT E476496 T1 ATE476496 T1 AT E476496T1
Authority
AT
Austria
Prior art keywords
modified
rem
lymphocytes
pbmc
rapid development
Prior art date
Application number
AT97914841T
Other languages
English (en)
Inventor
David Flyer
Kim Clary
Original Assignee
Calyx Bio Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calyx Bio Ventures Inc filed Critical Calyx Bio Ventures Inc
Priority claimed from PCT/US1997/003293 external-priority patent/WO1997032970A1/en
Application granted granted Critical
Publication of ATE476496T1 publication Critical patent/ATE476496T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AT97914841T 1996-03-04 1997-03-03 Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten ATE476496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3733396P 1996-03-04 1996-03-04
PCT/US1997/003293 WO1997032970A1 (en) 1996-03-04 1997-03-03 Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes

Publications (1)

Publication Number Publication Date
ATE476496T1 true ATE476496T1 (de) 2010-08-15

Family

ID=21893787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914841T ATE476496T1 (de) 1996-03-04 1997-03-03 Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten

Country Status (5)

Country Link
US (3) US6316257B1 (de)
EP (1) EP0904350B1 (de)
JP (1) JP2002516562A (de)
AT (1) ATE476496T1 (de)
DE (1) DE69739951D1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2003534283A (ja) * 2000-05-25 2003-11-18 エクサイト セラピーズ， インコーポレイテッド 天然で誘導されたかまたは人工的に誘導された免疫抑制後にｔ細胞免疫サーベイランスを回復もしくは増強するための方法
JP4231688B2 (ja) * 2000-08-16 2009-03-04 タカラバイオ株式会社 抗原特異的細胞傷害性ｔ細胞拡大培養方法
EP1390076A4 (de) * 2001-04-27 2004-12-15 Xcyte Therapies Inc Reifung antigen-präsentierender zellen mit aktivierten zellen
EP1401495A4 (de) * 2001-06-01 2005-11-23 Xcyte Therapies Inc T-zelleninduzierte gewebereparatur und regeneration
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
TWI311586B (en) * 2001-08-15 2009-07-01 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic t lumphocytes
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
EP2034009B1 (de) * 2002-02-08 2014-01-15 Life Technologies Corporation Zusammensetzungen und Verfahren zur Wiederherstellung der Immunreaktivität in Patienten mit immunologischen Defekten basierend auf CD3/CD28 costimulation
EP2305796B1 (de) 2002-03-25 2012-10-24 Takara Bio Inc. Verfahren zur Hestellung von zytotoxischen Lymphozyten
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004078928A2 (en) * 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
KR101331746B1 (ko) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
DK2573166T3 (da) 2004-02-26 2016-07-04 Immunovative Therapies Ltd Fremgangsmåder til fremstilling af T-celler til celleterapi
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2006050138A2 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
PT1814580T (pt) 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
EP1916302A4 (de) * 2005-08-17 2009-10-21 Takara Bio Inc Verfahren zur herstellung von lymphozyten
SI1941027T1 (sl) * 2005-09-28 2014-11-28 Ipd-Theapeutics B.V. Postopki in sredstva za proliferacijo zarodnih celic in kasnejšo generacijo in ekspanzijo progenitorskih celic, kot tudi izdelava efektor celic kot kliničnih zdravil
JP5156382B2 (ja) * 2005-09-30 2013-03-06 タカラバイオ株式会社 Ｔ細胞集団の製造方法
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
JP5666903B2 (ja) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
WO2009047003A1 (en) * 2007-10-12 2009-04-16 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Method and kit for rapid isolation of human foxp3+ treg cells
DE602007011626D1 (de) * 2007-10-12 2011-02-10 Max Delbrueck Centrum Verfahren und Kit zur schnellen Isolierung humaner Foxp3-Treg-Zellen
KR20090127973A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양 방법
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
US8558913B2 (en) * 2010-02-08 2013-10-15 Apple Inc. Capture condition selection from brightness and motion
NZ616405A (en) * 2011-04-08 2015-11-27 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
JP2021503885A (ja) * 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
CN120239746A (zh) 2022-09-19 2025-07-01 图恩疗法股份有限公司 用于调节t细胞功能的组合物、系统和方法
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544632A (en) 1981-06-12 1985-10-01 Yuichi Yamamura Human T cell lines and method of producing same
JPS59169489A (ja) 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
EP0147689B1 (de) 1983-12-05 1990-09-19 Asahi Kasei Kogyo Kabushiki Kaisha Verfahren zur Induktion von Antitumorimmunozyten, Verfahren zur Herstellung von Antitumorimmunozyten und durch das Verfahren hergestellte Antitumorimmunozyten
JPH02502424A (ja) 1987-03-11 1990-08-09 ザ・チルドレンズ・ホスピタル，インコーポレイテッド 抗原特異的ｔセルラインの調製法並びに治療のためのその使用
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6683046B1 (en) * 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ZA91463B (en) 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
WO1992005794A1 (en) 1990-09-28 1992-04-16 Immunex Corporation Method for producing th-independent cytotoxic t lymphocytes
DK0557459T3 (da) 1990-11-13 1997-12-15 Immunex Corp Bifunktionelle, selekterbare fusionsgener
DE4410136A1 (de) 1993-03-31 1994-10-06 Boehringer Mannheim Gmbh Tumorizide T-Lymphozyten
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2205430C (en) * 1994-11-17 2001-09-04 University Of South Florida Method for making a medicament for treating secondary immunodeficiency

Also Published As

Publication number Publication date
JP2002516562A (ja) 2002-06-04
US20050164387A1 (en) 2005-07-28
US6316257B1 (en) 2001-11-13
DE69739951D1 (de) 2010-09-16
US20020197716A1 (en) 2002-12-26
US6890753B2 (en) 2005-05-10
EP0904350A1 (de) 1999-03-31
EP0904350B1 (de) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE476496T1 (de) Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
MX9203439A (es) Una citocina mamifera, il-11
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
GEP20043163B (en) Inhibitors of Caspases, Pharmaceutical Composition on its Base and Method for its Production
NO993247D0 (no) FremgangsmÕte for fremstilling av tolterodin
PL320484A1 (en) Method of treating diabetes using kgf
EP0789588A4 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
ATE377022T1 (de) Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
ATE68001T1 (de) 11-beta-nitrat-substituierte estrane.
ES2191065T3 (es) Linfocitos t dirigidos.
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
IT8622548A0 (it) Procedimento d'epurazione e di deodorizzazione di gas e installazione per la messa in opera di questo procedimento.
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
DE69428909D1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
AU2824289A (en) Thienotricyclene for the treatment of bronchial diseases
ATE75610T1 (de) Pharmazeutische zubereitung zur behandlung des bluthochdrucks.
DE69504299D1 (de) Schneller Vermittler und Schnelles Vermittlungsverfahren
FR2604905B1 (fr) Procede d'obtention d'un epithelium gingival equivalent a partir de cellules humaines cultivees in vitro ainsi que les applications de cet epithelium en odontologie-stomatologie
DE3774947D1 (de) Alpha-acylamino-aminoalkyl-phosphonat-inhibitor des angiotensin umwandelnden enzyms.
ATE200424T1 (de) Verwendung von bk-riv-präparaten als arzneimittel zur therapie von aids
MX9800891A (es) Mocarhagina, una proteasa del veneno de cobra y usso terapeuticos de la misma.
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.
UA9690A (uk) Індуктор інтерферону першого типу в культурах клітин

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties